"&#xa0;\nIntroduction\nThe Society for General Microbiology (SGM) is a membership organisation for scientists who work in all areas of microbiology. It is the largest learned microbiological society in Europe with a worldwide membership based in universities, industry, hospitals, research institutes and schools. The SGM publishes key academic journals in microbiology and virology, organises international scientific conferences and provides an international forum for communication among microbiologists and supports their professional development. The Society promotes the understanding of microbiology to a diverse range of stakeholders, including policy-makers, students, teachers, journalists and the wider public, through a comprehensive framework of communication activities and resources. Further information about SGM is provided in Appendix 1.\n&#xa0;\nThe prevalence of antibiotic resistance should not surprise us. The problem is an inevitable consequence of human behaviour, evolutionary pressures and the ability of micro-organisms to rapidly change their genetic makeup. Despite this we believe that the scientific community – and broader society – is ingenious and determined enough to discover solutions that overcome the problems of antimicrobial resistance.\n&#xa0;\nOur emphasis in this consultation response is on the need for greater capacity in the basic research required to fight infection. Quite rightly basic research is proposed in the government’s \nUK Five Year Antimicrobial Resistance Strategy,\n \nas part of the overall solution to antibiotic resistance but details about how the research will be delivered were scarce. Basic research is, in our view, the only means of finding long-term solutions to the threat of antimicrobial resistance.\n&#xa0;\n1.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nHow has antimicrobial resistance developed in the past decade?\nIt is certain that micro-organisms can develop resistance to antimicrobial drugs; beyond this general statement, a more complex picture emerges in which some infections, notably, methicillin-resistant \nStaphylococcus aureus\n (MRSA) and HIV show, respectively, declining and stable levels of resistance, while others, notably tuberculosis, register increases.\n For a third, and very large group of infections, we have little or no data on resistance patterns: surveillance in these infections is not carried out. Treatment failure may be occurring, but neither it, nor antimicrobial resistance, is being \nsystematically reported.\n The most serious disease threats are from chronic infections including multidrug resistant tuberculosis, Gram-negative infections and hospital-acquired infections.\n&#xa0;\n2.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nWhat are the gaps in our knowledge about antimicrobial resistance?\n2.1.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nDiagnosis of antimicrobial resistance and routine surveillance of resistance rates\n2.2.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nExpanding the working life of existing antimicrobial treatments and developing new ones\n&#xa0;\n3.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nIs there sufficient research and investment into new antibiotics or other treatments and methods to ensure continued protection against infection? If not, how could this be rectified?\n&#xa0;\n4.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nWhat measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens?\nNo comment.\n&#xa0;\n5.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nWhat global coordination and action is required to fight antimicrobial resistance and is the UK contributing enough towards cross-border initiatives?\nNo comment.\n&#xa0;\n6.\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; \nWhat are the strengths and weaknesses of the Government’s 2013-2018 strategy for tackling antimicrobial resistance? What changes might be made to further strengthen the Government’s action plan?\n&#xa0;\nSociety for General Microbiology – Chair of the Policy Committee:&#xa0;\nSociety for General Microbiology – Policy Committee:&#xa0;\nThe Policy Committee additionally sought information from Dr Mike Dawson (Novacta Biosystems Ltd), Professor David Denning (University Hospital of South Manchester), Professor David Dunn (MRC Clinical Trials Unit), Dr Malcolm Rhodes (University of Manchester), Professor Jodi Lindsay (St George’s University of London), and Professor David Livermore (Lead, Antibiotic Resistance, Public Health England) in preparing this response.\n&#xa0;\nNovember 2013\n&#xa0;\n&#xa0;\nA world in which the science of microbiology provides maximum benefit to society.\n&#xa0;\nTo promote high-quality microbiological science, both nationally and internationally, to a diverse range of stakeholders.\n&#xa0;\nThe potential socio-economic benefits arising from microbiology are substantial. They include:\n&#xa0;\nTo achieve its Vision and Mission, the Society will work towards the strategic priorities below.\n&#xa0;\nThe Society is a Charity registered in England and Wales (No. 264017) and in Scotland (No.\nSC039250) and a Company Limited by Guarantee, registered in England and Wales (No.\n1039582).\n&#xa0;\n&#xa0;\n&#xa0;\n \nDepar\ntment of Health/\nDepartment for the Environment, Food and Rural Affairs\n,\n \nUK Five Year Antimicrobial Resistance Strategy 2013 to 2018\n; \nhttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf\n \n \nAlan P. Johnson, John Davies, Rebecca Guy, Julia Abernethy, Elizabeth Sheridan, Andrew Pearson and Georgia Duckworth (2012). \nMandatory surveillance of methicillin-resistant \nStaphylococcus aureus\n (MRSA) bacteraemia\n in England: the first 10 years. \nJournal of Antimicrobial Chemotherapy,\n doi: 10.1093/jac/dkr561 (Figure 1); \nhttp://jac.oxfordjournals.org/content/67/4/802.full\n. \nUK Collaborative Group on HIV Drug Resistance (2012). \nTime trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. \nBritish Medical Journal,\n \ndoi: 10.1136/bmj.e5253\n, \nhttp://www.bmj.com/content/345/bmj.e5253\n. Public Health England, July 2013, ‘\nNumber and proportion of tuberculosis cases with first line drug\n resistance, UK, 2000-2012’; \nhttp://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139697461\n.\n To the best of our knowledge, no comprehensive account of UK resistance rates has been published since 2007; \nwww.hpa.org.uk/Publications/InfectiousDiseases/AntimicrobialAndHealthcareAssociatedInfections/0712Antimicrobialresistance/\n.\n \nhttp://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-020.html\n \nhttp://blogs.nature.com/news/2012/05/europe-targets-superbugs-with-public-private-effort.html\n \n \nSociety for General Microbiology Consultation Response\n:\n Research and Development funding for science and technology in the UK\n, 28 August 2013. Please contact SGM for a list of firms.\n \nMichael G. Head, Joseph R. Fitchett, Mary K. Cooke, Fatima B. Wurie, Rifat Atun, Andrew C. Hayward, Alison Holmes, Alan P. Johnson, and Neil Woodford (2013). Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997-2010. \nJournal of Antimicrobial Chemotherapy,\n \ndoi: 10.1093/jac/dkt349\n, \nhttp://jac.oxfordjournals.org/content/early/2013/09/13/jac.dkt349.full\n. \nA word cloud available online shows this funding \nshortfall\n graphically\n - \nhttp://www.researchinvestments.org/\n. These data run until 2010 only; later data are not yet available.\n SGM can supply a full list of the initiatives we are aware about – please contact us. SGM currently collaborates with other learned societies on antimicrobial resistance; these include the Biochemical Society, British Society for Antimicrobial Chemotherapy, Royal Society of Chemistry, Society for Applied Microbiology and Society of Biology.\n \nAcademy of Sciences and Humanities in Hamburg/German National Academy of Sciences Leopoldina (2013). \nAntibiotics Research: Problems \nand Perspectives\n, p. 10; \nhttp://www.leopoldina.org/uploads/tx_leopublication/2013_06_17_Antibiotics_Research.pdf\n. \n \nAntibiotic Action (2013). Lessons to be \nlearnt from P\nharma\n about D\niscovery and \nD\nevelopment \nof N\new \nA\nntibacterial \nD\nrugs,\n p. 3; \nhttp://antibiotic-action.com/wp-content/uploads/2013/08/Learning-Lessons-report.pdf\n. \n \nDepar\ntment of Health/\nDepartment for the Environment, Food and Rural Affairs\n,\n \nUK Five Year Antimicrobial Resistance Strategy 2013 to 2018\n; \nhttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf\n \n For a programmatic statement of SGM’s current policy approach, please see: \nSociety for General Microbiology \nPolicy Note: Antimicrobial Resistance Policy, 7 June 2013; \nhttp://www.sgm.ac.uk/en/policy/consultation-responses.cfm\n. \n"